COMP <GO>
VRTX vs ABT // NET PROFIT MARGIN
Vertex Pharmaceuticals Incorporated (NASDAQ) VS. Abbott Laboratories (NYSE) • 15-METRIC TALLY: VRTX 8
— ABT 5
▲ NET PROFIT MARGIN LEADER: VRTX
LAST: $558.88 (+3.50%) • MKT CAP: $136.87B
net-margins
32.90%
LAST: $106.20 (+1.56%) • MKT CAP: $180.95B
net-margins
14.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VRTX VS. ABT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VRTX | ABT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 86.20% | 56.40% | +29.80 | VRTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.00% | 11.90% | +8.10 | VRTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 29.6x | 18.4x | +11.20 | ABT | /valuation <GO> |
| Free Cash Flow Yield | 2.33% | 4.09% | -1.76 | ABT | /fcf-yield <GO> |
| Operating Margin | 34.80% | 18.20% | +16.60 | VRTX | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 32.90% | 14.70% | +18.20 | VRTX | /net-margins <GO> |
| Revenue Growth (YoY) | 8.90% | 5.70% | +3.20 | VRTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.86 | 4.36 | +9.50 | VRTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.7 | 54.2 | +3.50 | VRTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 0.99 | +0.03 | VRTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.2x | 25.8x | +6.40 | ABT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $136.87B | $180.95B | -$44.08B | ABT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VRTX REV | ABT REV | VRTX GROSS % | ABT GROSS % | VRTX FCF | ABT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.00B | $44.33B | 86.2% | 56.4% | $3.19B | $7.39B |
| FY 2024 | $11.02B | $41.95B | 86.1% | 55.4% | -$790.3M | $6.35B |
| FY 2023 | $9.87B | $40.11B | — | — | $3.09B | $5.46B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VRTX // BETA 1.02
ABT // BETA 0.99